Docetaxel plus cisplatin is effective for patients with metastatic breast cancer resistant to previous anthracycline treatment: a phase II clinical trial

Table 1 Patient characteristics

	No.	%
Patients
Treated	39	100.0
Evaluable for response	36	92.3
Age
Median (years)	51.3
Range	41.2 – 64.1
ECOG performance status
0	3	7.7
1	27	69.2
2	9	23.1
Site(s) of metastatic lesion(s)*
Lung	27	69.2
Liver	9	23.1
Lymph node	15	38.5
Soft tissue	3	7.7
Bone	24	61.5
Brain	3	7.7
Response to prior anthracyclines
Primary resistant	24	61.5
Secondary resistant	15	38.5
Interval from the cessation of last chemotherapy
Median (months)	4.1
Range	1.0 – 11.2
No. of prior chemotherapy regimens
Hormonal therapy (total)	20	51.3
1	9	23.1
2	21	53.8
3 or more	9	23.1
Characteristics of prior chemotherapy†
CMF	24
CAF	15
FEC	9
VE	21
High-dose therapy with stem cell rescue	6
AT	3

* Because patients could have metastases at multiple sites, the total numbers of metastases are greater than the number of patients.
† CMF, cyclophosphamide 600 mg/m², methotrexate 40 mg/m², 5-fluorouracil 600 mg/m², days 1 & 8, every 4 weeks; CAF, cyclophosphamide 500 mg/m², doxorubicin 50 mg/m², 5-fluorouracil 500 mg/m², every 3 weeks; FEC, 5-fluorouracil 600 mg/m², epirubicin 60 mg/m², cyclophosphamide 600 mg/m², every 4 weeks; VE, vinorelbine 25 mg/m², days 1 & 8, epirubicin 60 mg/m² day 1, every 3 weeks; AT, doxorubicin 50 mg/m², paclitaxel 175 mg/m², every 3 weeks.

ISSN: 1471-2407